Advanced Solid Tumors Clinical Trial
Official title:
A Phase 1 Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
This is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib.
The study is only enrolling patients in the expanded cohorts with hepatocellular carcinoma,
renal cell carcinoma, melanoma, non-small cell lung cancer, and breast cancer.
Enrollment of an initial patient cohort of 3 or 6 patients will follow the traditional "3 +
3" dose escalation scheme. These patients will be treated with ARQ 197 and sorafenib at Dose
Level 1 (ARQ 197 360 mg BID and sorafenib 200 mg BID). Enrollment of subsequent patient
cohort(s) will depend on the safety and tolerability of the combination treatment in the
initial cohort. If <33% patients treated at Dose Level 1 experience dose-limiting
toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6
patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg BID and sorafenib 400
mg BID). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first
treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0
(ARQ 197 240 mg BID and sorafenib 200 mg BID).
Additional treatment cohorts may be enrolled to explore intermediate, higher or lower doses
of ARQ 197, as indicated by the tolerability, safety profile, and pharmacokinetic (PK)
profile.
Intra-patient dose-escalation from Dose Level 1 to Dose Level 2 may occur in patients
enrolled in Dose Level 1 after they complete at least 1 cycle of treatment without DLT and
other drug-related adverse event that, in the opinions of Investigator and Medical Monitor,
is serious and medically significant.
Once a safe and recommended dose level is determined, an expanded cohort (Expansion Cohort
1) of up to 40 patients with either unresectable HCC or advanced renal cell carcinoma (RCC),
for whom sorafenib is indicated, will be enrolled and treated at this dose level (expansion
portion). Up to 20 patients with unresectable HCC and up to 20 patients with advanced RCC
may be enrolled in this protocol (including patients in dose-escalation cohorts and
expansion cohort).
An additional expansion cohort (Expansion Cohort 2) of up to 40 patients with breast cancer,
non-small cell lung cancer or melanoma will be enrolled and treated at MTD/RP2D. Up to 10
patients may be enrolled for breast and non-small cell lung cancer and up to 20 patients
with melanoma (at least 10 of whom must have NRAS mutation).
Under Amendment #3, newly enrolled subjects with HCC will be given ARQ 197 at 240 mg BID as
starting dose. If a patient with HCC tolerates this starting dose for at least one cycle,
the investigator may increase his/her dose to 360 mg BID.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04972981 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT05086822 -
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT03260322 -
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05862831 -
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03641794 -
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT03665129 -
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05914116 -
A Study of DB-1311 in Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01693562 -
A Phase 1/2 Study to Evaluate MEDI4736
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04387916 -
A Study of KC1036 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04095273 -
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
|
Phase 1 | |
| Not yet recruiting |
NCT03692520 -
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02997176 -
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
|
Phase 1 | |
| Recruiting |
NCT04446260 -
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT02253992 -
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06076291 -
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT03545971 -
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT00962091 -
Study of MLN8237 in Participants With Advanced Solid Tumors
|
Phase 1 |